Tag: Health care industry
-
Cramer: Here are 3 defensive stock market moves I’m making as oil and rates surge
CNBC’s Jim Cramer is taking a more defensive approach as rising oil prices, higher interest rates and geopolitical tensions create a tougher backdrop.
-
After a sell-off, this medical device stock looks like a gift for patient investors
Overblown fears surrounding GLP-1 weight loss drugs were already pressuring the stock when an onboarding stumble triggered a sell-off.
-
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
The string of deals builds on the Trump administration’s push to link the nation’s drug prices to cheaper ones abroad.
-
Labor Department to propose expansion of association health plans, which could lower insurance costs for some workers
The agency has submitted a rule proposal to the White House that could allow more workers to get health insurance through association health plans.
-
BioCryst is profitable. Now it wants to buy more rare disease drugs
Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.
-
How Taylor Farms became integral to America’s food supply system
Taylor Farms and other suppliers have become larger and more integral to the U.S. food system, complicating foodborne illnesses such as cyclosporiasis.
-
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.
-
HHS plans new FDA deputy commissioner roles for technology and drugs, sources say
HHS plans to name two deputy commissioners for technology and drugs, said two sources familiar with the matter.
-
Most Americans aren’t anti-vaccine. They’re uncertain — and that’s a growing public health challenge
The bigger issue at hand may be that many Americans fall into a large, uncertain middle ground – neither firmly pro-vaccine nor staunchly opposed.
-
BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment
BioMarin will acquire Alesta Therapeutics for $275 million upfront, bolstering BioMarin’s unit focused on rare skeletal conditions.
Latest News
Stay Connected
Categories
BBC News CNA CNBC CNN International Deutsche Welle (DW) Euronews France 24 General Global & European Specialized & Regional
Tags
amp Artificial intelligence Asia Breaking News: Business Breaking News: Markets Breaking News: Politics Breaking News: Technology Business business news cent china cup Donald J. Trump Donald Trump economy European Union fast football France germany Investment strategy iran Iran war markets news People per politics return russia said Singapore spain Sport Stock markets technology trump ukraine United States US-Israel attack on Iran 2026 video War in Ukraine World world cup World Cup 2026
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
